Oxford Centre for Haematology
The OCH Management Board has as members the Director of the OCH, the Head of Clinical Haematology, the Head of Laboratory Haematology, the Head of the Radcliffe Department of Medicine, the Head of the Nuffield Division of Clinical Laboratory Sciences, the Director of the MRC Molecular Haematology Unit, the Director of the MRC Human Immunology Unit, the RDM Research Strategy Coordinator and the Administrator of the OCH.
Chromatin accessibility governs the differential response of cancer and T cells to arginine starvation.
Crump NT. et al, (2021), Cell Rep, 35
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.
Bernard E. et al, (2021), Nat Med
Single Cell Analysis Resolves Genetic and Transcriptional Heterogeneity in Myeloproliferative Neoplasms
Rodriguez-Meira A. et al, (2021), Experimental Hematology, 64
HYPOMETHYLATING AGENT IN A PATIENT WITH MDS/MPN-RS-T
Papadopoulou T. et al, (2021)
ACUTE MONOBLASTIC LEUKEMIA IN AN ELDERLY PATIENT WITH HEMOPHILIA A: A CASE REPORT
SOUSOS N. et al, (2021)
30 March 2021
Dr Bethan Psaila and her team will investigate the potential of circulating blood platelets for early detection of a range of cancer types.
3 February 2021
Dr Noemi Roy has received funding in the 2020-21 round of the Public Engagement with Research Seed Fund as one of seven projects for innovative work to engage the public with medical research.
28 June 2021: Oxford Centre for Haematology Annual Meeting
Please email for further information